Prescription Weight Loss Pills Eligibility Private prescription: BMI 30+, or BMI 27+ with at least one weight-related comorbidity (PCOS, hypertension, dyslipidaemia, type 2 diabetes, sleep apnoea) NHS (Orlistat): BMI 30+, or BMI 28+ with additional risk factors NHS (GLP-1 injections via specialist services): BMI 35+ with at least one comorbidity Where injections win - Highest efficacy - Mounjaro and Wegovy 7.2mg injection currently outperform both oral options on average weight loss Already available in the UK Weekly dosing No fasting requirements When pills make more sense - Genuine needle phobia Frequent travel where cold storage is difficult Pills draw less attention than injectable pens You take levothyroxine and orforglipron suits your existing morning routine better than the Wegovy pill Well let you decide whats better
Badawi GH, Kawano N, Yamauchi Y, Shimada E, Sasaki R, Kubo A, Tanaka K
& Tseng, L
Research applications Research applications Investigation of FOXO4p53 interaction disruption and downstream apoptotic signaling In vitro studies of cellular senescence, senolysis, and age-related cell clearance Combination studies with chemotherapeutics, targeted agents, or senolytic compounds Mechanistic assays of apoptosis markers, mitochondrial dysfunction, and cell viability For laboratory research use only
